{"id":"bol-303259-x","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Vision-related adverse events"}]},"_chembl":{"chemblId":"CHEMBL2364612","moleculeType":"Small molecule","molecularWeight":"507.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets complement component C5, a key node in the complement cascade that drives inflammatory responses. By blocking C5 activation, it prevents the formation of the membrane attack complex and reduces recruitment of inflammatory cells to ocular tissues. This mechanism is intended to treat complement-mediated inflammatory and degenerative eye diseases.","oneSentence":"BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:43:59.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Geographic atrophy (age-related macular degeneration)"}]},"trialDetails":[{"nctId":"NCT04140279","phase":"PHASE4","title":"A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension","status":"WITHDRAWN","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-05-13","conditions":"Ocular Hypertension","enrollment":""},{"nctId":"NCT03931317","phase":"NA","title":"Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2018-12-03","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":70},{"nctId":"NCT03949244","phase":"PHASE4","title":"Nailfold Capillary Blood Flow With Latanoprost Bunod","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-08-15","conditions":"Glaucoma, Open-Angle","enrollment":47},{"nctId":"NCT01749930","phase":"PHASE3","title":"Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01749904","phase":"PHASE3","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01-31","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01707381","phase":"PHASE2","title":"BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":25},{"nctId":"NCT01895972","phase":"PHASE3","title":"Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-07-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":130},{"nctId":"NCT01223378","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-12-13","conditions":"Intraocular Pressure","enrollment":413},{"nctId":"NCT01895985","phase":"PHASE1","title":"Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-07","conditions":"Intraocular Pressure","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["latanoprostene bunod"],"phase":"phase_3","status":"active","brandName":"BOL-303259-X","genericName":"BOL-303259-X","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye. Used for Geographic atrophy (age-related macular degeneration).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}